Merrimack Will Present Extensive Oncology Pipeline at ASCO

Merrimack Pharmaceuticals, Inc.

today announced that it will present on its extensive oncology pipeline at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2016 at McCormick Place, Chicago, Illinois. Final results from a Phase 1 study evaluating the safety, pharmacology and initial efficacy of MM-151 will be presented in a Poster Discussion Session. Merrimack will also present on the results from its Phase 3 NAPOLI-1 study of ONIVYDE®, as well as on multiple therapeutic candidates from its antibody engineering and antibody-directed nanotherapeutic (ADN) technology platforms in six poster sessions. Poster Discussion Session: Final results of a first-in-human study evaluating the safety, pharmacology and initial efficacy of MM-151, an oligoclonal anti-EGFR antibody in patients with refractory solid tumors (Abstract 2518) Session Title: Poster Discussion Session, Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics Sunday, June 5, 2016, 11:30 AM - 12:45 PM CT Location: Arie Crown Theater Poster Sessions: Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposmal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy (Abstract 4126) Session Title: Gastrointestinal (Noncolorectal) Cancer Saturday, June 4, 2016, 8:00 AM – 11:30 AM CT Location: Hall A Randomized Phase 2 study of paclitaxel (PTX), trastuzumab (T) with or without MM-111 in HER2 expressing gastroesophageal cancers (GEC) (Abstract 4043) Session Title: Gastrointestinal (Noncolorectal) Cancer Saturday, June 4, 2016, 8:00 AM – 11:30 AM CT Location: Hall A A Phase 1b/2 study combining MM-151 + nal-IRI + 5-FU + leucovorin in RAS-wild type metastatic colorectal cancer (mCRC) (Abstract TPS3633) Session Title: Gastrointestinal (Colorectal) Cancer Saturday, June 4, 2016, 8:00 AM – 11:30 AM CT Location: Hall A SHERLOC: A Phase 2 study of seribantumab (MM-121) in combination with docetaxel or pemetrexed versus docetaxel or pemetrexed alone in patients with heregulin positive (HRG+), locally advanced or metastatic non-small cell lung cancer (NSCLC) (Abstract TPS9110) Session Title: Lung Cancer – Non-Small Cell Metastatic Saturday, June 4, 2016, 8:00 AM – 11:30 AM CT Location: Hall A HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1) (Abstract TPS631) Session Title: Breast Cancer – HER2/ER Sunday, June 5, 2016, 8:00 AM – 11:30 AM CT Location: Hall A A Phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers (Abstract TPS11619) Session Title: Tumor Biology Monday, June 6, 2016, 1:00 PM – 4:30 PM CT Location: Hall A